Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations

v3.20.2
Consolidated Statements of Operations - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Operating expenses:        
Research and development $ 4,706,012 $ 5,250,327 $ 15,354,453 $ 14,161,543
General and administrative 2,607,472 2,376,248 8,186,169 7,234,244
Total operating expenses 7,313,484 7,626,575 23,540,622 21,395,787
Loss from operations (7,313,484) (7,626,575) (23,540,622) (21,395,787)
Other income (expense):        
Interest income 58,451 80,747 154,019 334,307
Other income (expense) 9,609   (2,165,044)  
Change in fair value of warrant liabilities 10,689,855 2,186,710 3,800,356 18,622,471
Total other income 10,757,915 2,267,457 1,789,331 18,956,778
Net income (loss) $ 3,444,431 $ (5,359,118) $ (21,751,291) $ (2,439,009)
Basic net income (loss) per share $ 0.12 $ (0.67) $ (1.03) $ (0.31)
Shares used in computing basic net income (loss) per share 27,809,169 7,940,931 21,069,057 7,940,931
Diluted net loss per share $ (0.19) $ (0.67) $ (1.03) $ (0.31)
Shares used in computing diluted net loss per share 29,079,107 7,940,931 21,069,057 7,940,931